Recipient HLA-DR3, tumour necrosis factor-α promoter allele-2 (tumour necrosis factor-2) and cytomegalovirus infection are interrelated risk factors for chronic rejection of liver grafts

被引:19
作者
Evans, PC
Smith, S
Hirschfield, G
Rigopoulou, E
Wreghitt, TG
Wight, DGD
Taylor, CJ
Alexander, GJM
机构
[1] Univ Cambridge, Addenbrookes NHS Trust, Sch Clin Med, Dept Med, Cambridge, England
[2] Univ Cambridge, Addenbrookes NHS Trust, Sch Clin Med, Dept Surg, Cambridge, England
[3] Univ Cambridge, Addenbrookes NHS Trust, Sch Clin Med, Clin Microbiol & Publ Hlth Lab, Cambridge, England
[4] Univ Cambridge, Addenbrookes NHS Trust, Sch Clin Med, Dept Histopathol, Cambridge, England
关键词
liver transplant; chronic rejection; HLA-DR3; tumour necrosis factor-alpha; cytomegalovirus;
D O I
10.1016/S0168-8278(00)00101-X
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background/Aims: The tumour necrosis factor (TNF)-2 promoter allele, which elicits elevated expression of TNF-a, is in linkage disequilibrium with the extended haplotype HLA-A1-B8-DR3-DQ2. TNF-2 and HLA-DR3 have been implicated in renal and cardiac graft rejection and loss. Cytomegalovirus (CMV) infection has been associated with chronic allograft rejection. We examined the relationship between HLA-DR3, promoter allele TNF-2 and cytomegalovirus in relation to chronic rejection following liver transplantation. Methods: (i) Retrospective analysis of HLA-DR3 was performed in 307 liver transplant recipients and 283 donors. (ii) Prospective analysis of TNF-ar promoter allele status, HLA-DR3 status and cytomegalovirus infection was assessed in 123 recipients. Results: (i) Retrospective analysis, Recipient HLA-DR3 (relative risk 1.9; 95% C.I. 1.01-3.58) was a risk factor for chronic rejection, (ii) Prospective analysis. Recipient HLA-DR3 was a risk factor for chronic rejection (relative risk 3.41; 95% C.I. 1.66-7.03) which was elevated further by superimposed CMV infection (relative risk 5.01; 95% C.I. 2-12.55). Recipient TNF-2 was associated,vith chronic rejection (relative risk 2.29; 95% C,I, 0.9-5.83) through linkage to HLA-DR3. Conclusions: Recipient HLA-DR3, TNF-2 status and CMV infection were inter-related risk factors for chronic rejection of liver grafts. (C) 2001 European Association for the Study of the Liver. Published by Elsevier Science B,V, All rights reserved.
引用
收藏
页码:711 / 715
页数:5
相关论文
共 29 条
[1]   SEX MISMATCH AS A RISK FACTOR FOR CHRONIC REJECTION OF LIVER ALLOGRAFTS [J].
CANDINAS, D ;
GUNSON, BK ;
NIGHTINGALE, P ;
HUBSCHER, S ;
MCMASTER, P ;
NEUBERGER, JM .
LANCET, 1995, 346 (8983) :1117-1121
[2]   IN-VITRO CYTOKINE PRODUCTION BY HLA-B8,DR3 POSITIVE SUBJECTS [J].
CANDORE, G ;
CIGNA, D ;
GERVASI, F ;
COLUCCI, AT ;
MODICA, MA ;
CARUSO, C .
AUTOIMMUNITY, 1994, 18 (02) :121-132
[3]   HLA-B8,DR3 haplotype affects lymphocyte blood levels [J].
Caruso, C ;
Bongiardina, C ;
Candore, G ;
Cigna, D ;
Romano, GC ;
Colucci, AT ;
DiLorenzo, G ;
Gervasi, F ;
Manno, M ;
Potestio, M ;
Tantillo, G .
IMMUNOLOGICAL INVESTIGATIONS, 1997, 26 (03) :333-340
[4]  
DALFONSO S, 1994, IMMUNOGENETICS, V39, P150
[5]  
Demetris A, 2000, Hepatology, V31, P792
[6]   POLYMORPHISM IN THE HUMAN-COMPLEMENT C4 GENES AND GENETIC SUSCEPTIBILITY TO AUTOIMMUNE HEPATITIS [J].
DOHERTY, DG ;
UNDERHILL, JA ;
DONALDSON, PT ;
MANABE, K ;
MIELIVERGANI, G ;
EDDLESTON, ALWF ;
VERGANI, D ;
DEMAINE, AG ;
WILLIAMS, R .
AUTOIMMUNITY, 1994, 18 (04) :243-249
[7]   DUAL ASSOCIATION OF HLA DR2 AND DR3 WITH PRIMARY SCLEROSING CHOLANGITIS [J].
DONALDSON, PT ;
FARRANT, JM ;
WILKINSON, ML ;
HAYLLAR, K ;
PORTMANN, BC ;
WILLIAMS, R .
HEPATOLOGY, 1991, 13 (01) :129-133
[8]   High incidence of antitissue antibodies in patients experiencing chronic liver allograft rejection [J].
Dubel, L ;
Farges, O ;
Johanet, C ;
Sebagh, M ;
Bismuth, H .
TRANSPLANTATION, 1998, 65 (08) :1072-1075
[9]  
DYER PA, 1985, TRANSPLANT P, V17, P2248
[10]   Qualitative and semiquantitative polymerase chain reaction testing for cytomegalovirus DNA in serum allows prediction of CMV related disease in liver transplant recipients [J].
Evans, PC ;
Soin, A ;
Wreghitt, TG ;
Alexander, GJM .
JOURNAL OF CLINICAL PATHOLOGY, 1998, 51 (12) :914-921